{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:10:44Z","timestamp":1768266644787,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Conditioning with treosulfan and fludarabine (Treo\/Flu) has been proven to be feasible and efficient in several types of malignancies before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Given its favorable reduced toxicity profile, we introduced Treo\/Flu as conditioning before autologous HSCT (auto-HSCT) in patients with B-cell Non-Hodgkin lymphoma (NHL). The aim of this study was to evaluate the efficacy and safety of Treo\/Flu in comparison to TEAM. Fifty-seven patients with NHL received auto-HSCT after conditioning with either Treo\/Flu (<jats:italic>n<\/jats:italic>\u2009=\u200922) or TEAM (<jats:italic>n<\/jats:italic>\u2009=\u200935). All patients achieved sustained engraftment. PFS, EFS and OS were not significant in both groups. Of note is that patients in the Treo\/Flu group were less dependent on thrombocyte transfusions (<jats:italic>p<\/jats:italic>\u2009=\u20090.0082), significantly older (in median 11 years, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and suffered less frequently from infectious complications (<jats:italic>p<\/jats:italic>\u2009=\u20090.0105), mucositis and stomatitis (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). This study is the first to present efficacy, feasibility, and safety of conditioning with Treo\/Flu preceding auto-HSCT in patients with NHL. Since it demonstrated a lack of significant difference in comparison to TEAM conditioning it might be a valuable alternative especially in elderly patients with B-cell NHL and comorbidities. Further evaluation by prospective clinical trials is warranted.<\/jats:p>","DOI":"10.1038\/s41409-022-01701-x","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T12:05:28Z","timestamp":1652184328000},"page":"1164-1170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1476-8059","authenticated-orcid":false,"given":"Jochen J.","family":"Frietsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Miethke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Linke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl C.","family":"Crodel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Schnetzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2038-9730","authenticated-orcid":false,"given":"Inken","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"1701_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298\u2013310. https:\/\/doi.org\/10.1016\/S0140-6736(16)32407-2. e-pub ahead of print 2017\/02\/06.","journal-title":"Lancet"},{"key":"1701_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00403-1","volume":"11","author":"S Harrysson","year":"2021","unstructured":"Harrysson S, Eloranta S, Ekberg S, Enblad G, Jerkeman M, Wahlin BE, et al. Incidence of relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11:9 https:\/\/doi.org\/10.1038\/s41408-020-00403-1. e-pub ahead of print 2021\/01\/09.","journal-title":"Blood Cancer J"},{"key":"1701_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","volume":"12","author":"U Zahid","year":"2017","unstructured":"Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12:217\u201326. https:\/\/doi.org\/10.1007\/s11899-017-0382-1. e-pub ahead of print 2017\/05\/10.","journal-title":"Curr Hematol Malig Rep"},{"key":"1701_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/hon.13_2629","volume":"42","author":"M Dreyling","year":"2019","unstructured":"Dreyling M, Zoellner AK, Stilgenbauer S, Hubel K, Thieblemont C, Metzner B. et al. Autologous stem cell transplantation in first remission significantly prolongs progression-free and overall survival in mantle-cell lymphoma (MCL). Oncol Res Treat. 2019;42:186\u2013186. https:\/\/doi.org\/10.1002\/hon.13_2629.","journal-title":"Oncol Res Treat"},{"key":"1701_CR5","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677\u201384. https:\/\/doi.org\/10.1182\/blood-2004-10-3883. e-pub ahead of print 2004\/12\/14.","journal-title":"Blood"},{"key":"1701_CR6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","volume":"13","author":"W Mills","year":"1995","unstructured":"Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1995;13:588\u201395. https:\/\/doi.org\/10.1200\/JCO.1995.13.3.588. e-pub ahead of print 1995\/03\/01.","journal-title":"J Clin Oncol"},{"key":"1701_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","volume":"20","author":"MD Caballero","year":"1997","unstructured":"Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transpl. 1997;20:451\u20138. https:\/\/doi.org\/10.1038\/sj.bmt.1700913. e-pub ahead of print 1997\/10\/06.","journal-title":"Bone Marrow Transpl"},{"key":"1701_CR8","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1080\/10428194.2020.1765238","volume":"61","author":"F Marchesi","year":"2020","unstructured":"Marchesi F, Capria S, Pedata M, Terrenato I, Ballotta L, Riccardi C, et al. BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant. Leuk Lymphoma. 2020;61:2238\u201341. https:\/\/doi.org\/10.1080\/10428194.2020.1765238. e-pub ahead of print 2020\/05\/19.","journal-title":"Leuk Lymphoma"},{"key":"1701_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/bmt.2015.273","volume":"51","author":"L Sellner","year":"2016","unstructured":"Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transpl. 2016;51:212\u20138. https:\/\/doi.org\/10.1038\/bmt.2015.273. e-pub ahead of print 2015\/11\/17.","journal-title":"Bone Marrow Transpl"},{"key":"1701_CR10","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1182\/bloodadvances.2021004863","volume":"5","author":"J Duque-Afonso","year":"2021","unstructured":"Duque-Afonso J, Ewald S, Ihorst G, Waterhouse M, Struessmann T, Zeiser R. et al. The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Adv. 2021;5:4327\u201337. https:\/\/doi.org\/10.1182\/bloodadvances.2021004863.","journal-title":"Blood Adv"},{"key":"1701_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/sj.bmt.1705605","volume":"39","author":"M Schmidt-Hieber","year":"2007","unstructured":"Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H, et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transpl. 2007;39:389\u201396. https:\/\/doi.org\/10.1038\/sj.bmt.1705605. e-pub ahead of print 2007\/02\/21.","journal-title":"Bone Marrow Transpl"},{"key":"1701_CR12","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1200\/JCO.2009.23.3429","volume":"28","author":"J Casper","year":"2010","unstructured":"Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, et al. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan\/fludarabine conditioning. J Clin Oncol. 2010;28:3344\u201351. https:\/\/doi.org\/10.1200\/JCO.2009.23.3429. e-pub ahead of print 2010\/05\/26.","journal-title":"J Clin Oncol"},{"key":"1701_CR13","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3324\/haematol.2011.043810","volume":"96","author":"T Ruutu","year":"2011","unstructured":"Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, et al. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica. 2011;96:1344\u201350. https:\/\/doi.org\/10.3324\/haematol.2011.043810. e-pub ahead of print 2011\/06\/11.","journal-title":"Haematologica"},{"key":"1701_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1182\/blood-2002-11-3615","volume":"103","author":"J Casper","year":"2004","unstructured":"Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004;103:725\u201331. https:\/\/doi.org\/10.1182\/blood-2002-11-3615. e-pub ahead of print 2003\/08\/30.","journal-title":"Blood"},{"key":"1701_CR15","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Remenyi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7:e28\u2013e39. https:\/\/doi.org\/10.1016\/S2352-3026(19)30157-7. e-pub ahead of print 2019\/10\/14.","journal-title":"Lancet Haematol"},{"key":"1701_CR16","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1111\/bjh.16642","volume":"189","author":"C Gran","year":"2020","unstructured":"Gran C, Wang J, Nahi H, Koster L, Gahrton G, Einsele H. et al. Treosulfan conditioning for allogeneic transplantation in multiple myeloma \u2013 improved overall survival in first line haematopoietic stem cell transplantation \u2013 a large retrospective study by the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2020;189:e213\u20137. https:\/\/doi.org\/10.1111\/bjh.16642.","journal-title":"Br J Haematol"},{"key":"1701_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/sj.bmt.1704626","volume":"34","author":"M Koenigsmann","year":"2004","unstructured":"Koenigsmann M, Mohren M, Jentsch-Ullrich K, Franke A, Becker E, Heim M. et al. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant. 2004;34:477\u201383. https:\/\/doi.org\/10.1038\/sj.bmt.1704626.","journal-title":"Bone Marrow Transplant"},{"key":"1701_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/bmt.2013.199","volume":"49","author":"M Koenigsmann","year":"2014","unstructured":"Koenigsmann M, Casper J, Kahl C, Basara N, Sayer HG, Behre G. et al. Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed\/refractory aggressive NHL: a prospective phase-II trial. Bone Marrow Transplant. 2014;49:410\u20135. https:\/\/doi.org\/10.1038\/bmt.2013.199.","journal-title":"Bone Marrow Transplant"},{"key":"1701_CR19","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/bmt.2015.174","volume":"50","author":"R Yerushalmi","year":"2015","unstructured":"Yerushalmi R, Shem-Tov N, Danylesko I, Avigdor A, Nagler A, Shimoni A. Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies. Bone Marrow Transpl. 2015;50:1526\u201335. https:\/\/doi.org\/10.1038\/bmt.2015.174. e-pub ahead of print 2015\/08\/04.","journal-title":"Bone Marrow Transpl"},{"key":"1701_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3892\/mco.2014.300","volume":"2","author":"M Schmitt","year":"2014","unstructured":"Schmitt M, Trenschel R, Sayer HG, Schneider C, Glass A, Hilgendorf I, et al. Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma. Mol Clin Oncol. 2014;2:773\u201382. https:\/\/doi.org\/10.3892\/mco.2014.300. e-pub ahead of print 2014\/07\/24.","journal-title":"Mol Clin Oncol"},{"key":"1701_CR21","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365. https:\/\/doi.org\/10.1182\/blood-2003-12-4434. e-pub ahead of print 2004\/05\/06.","journal-title":"Blood"},{"key":"1701_CR22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P.","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl J Med. 1993;329:987\u201394. https:\/\/doi.org\/10.1056\/NEJM199309303291402. e-pub ahead of print 1993\/09\/30.","journal-title":"N. Engl J Med"},{"key":"1701_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558\u201365. https:\/\/doi.org\/10.1182\/blood-2007-06-095331. e-pub ahead of print 2007\/10\/27.","journal-title":"Blood"},{"key":"1701_CR24","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004. e-pub ahead of print 2005\/07\/05.","journal-title":"Blood"},{"key":"1701_CR25","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/bmt.2011.242","volume":"47","author":"J Casper","year":"2012","unstructured":"Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T, et al. Allogeneic hematopoietic SCT in patients with AML following treosulfan\/fludarabine conditioning. Bone Marrow Transpl. 2012;47:1171\u20137. https:\/\/doi.org\/10.1038\/bmt.2011.242. e-pub ahead of print 2011\/12\/14.","journal-title":"Bone Marrow Transpl"},{"key":"1701_CR26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/bmt.2014.39","volume":"49","author":"M Mohty","year":"2014","unstructured":"Mohty M, Hubel K, Kroger N, Aljurf M, Apperley J, Basak GW, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2014;49:865\u201372. https:\/\/doi.org\/10.1038\/bmt.2014.39. e-pub ahead of print 2014\/04\/02.","journal-title":"Bone Marrow Transpl"},{"key":"1701_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/sj.bmt.1703389","volume":"29","author":"SN Wolff","year":"2002","unstructured":"Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transpl. 2002;29:545\u201352. https:\/\/doi.org\/10.1038\/sj.bmt.1703389. e-pub ahead of print 2002\/04\/30.","journal-title":"Bone Marrow Transpl"},{"key":"1701_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/bjh.14190","volume":"175","author":"HM Teltschik","year":"2016","unstructured":"Teltschik HM, Heinzelmann F, Gruhn B, Feuchtinger T, Schlegel P, Schumm M, et al. Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients. Br J Haematol. 2016;175:115\u201322. https:\/\/doi.org\/10.1111\/bjh.14190. e-pub ahead of print 2016\/06\/25.","journal-title":"Br J Haematol"},{"key":"1701_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl. 2007;40:381\u20137. https:\/\/doi.org\/10.1038\/sj.bmt.1705727. e-pub ahead of print 2007\/06\/15.","journal-title":"Bone Marrow Transpl"},{"key":"1701_CR30","first-page":"1023","volume":"61","author":"SA Rosenberg","year":"1977","unstructured":"Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin\u2019s lymphomas. Cancer Treat Rep. 1977;61:1023\u20137. e-pub ahead of print 1977\/09\/01.","journal-title":"Cancer Treat Rep"},{"key":"1701_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-020-01018-6","volume":"14","author":"M Lumish","year":"2021","unstructured":"Lumish M, Falchi L, Imber BS, Scordo M, von Keudell G, Joffe E. How we treat mature B-cell neoplasms (indolent B-cell lymphomas). J Hematol Oncol. 2021;14:5 https:\/\/doi.org\/10.1186\/s13045-020-01018-6. e-pub ahead of print 2021\/01\/08.","journal-title":"J Hematol Oncol"},{"key":"1701_CR32","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","volume":"98","author":"S Montoto","year":"2013","unstructured":"Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, Lopez-Guillermo A, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98:1014\u201321. https:\/\/doi.org\/10.3324\/haematol.2013.084723. e-pub ahead of print 2013\/07\/03.","journal-title":"Haematologica"},{"key":"1701_CR33","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","volume":"24","author":"V Jurinovic","year":"2018","unstructured":"Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the german low grade lymphoma study group. Biol Blood Marrow Transpl. 2018;24:1172\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2018.03.022. e-pub ahead of print 2018\/04\/02.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1701_CR34","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","volume":"20","author":"PB Dahi","year":"2014","unstructured":"Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transpl. 2014;20:2004\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2014.08.019. e-pub ahead of print 2014\/09\/02.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1701_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7326\/0003-4819-90-2-191","volume":"90","author":"JR Durant","year":"1979","unstructured":"Durant JR, Norgard MJ, Murad TM, Bartolucci AA, Langford KH. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med. 1979;90:191\u20134. https:\/\/doi.org\/10.7326\/0003-4819-90-2-191. e-pub ahead of print 1979\/02\/01.","journal-title":"Ann Intern Med"},{"key":"1701_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3960\/jslrt.56.100","volume":"56","author":"E Kondo","year":"2016","unstructured":"Kondo E. Autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma. J Clin Exp Hematop. 2016;56:100\u20138. https:\/\/doi.org\/10.3960\/jslrt.56.100.","journal-title":"J Clin Exp Hematop"},{"key":"1701_CR37","doi-asserted-by":"publisher","first-page":"916.e911","DOI":"10.1016\/j.jtct.2021.07.020","volume":"27","author":"I Sakellari","year":"2021","unstructured":"Sakellari I, Gavriilaki E, Mallouri D, Batsis I, Varelas C, Tagara S. et al. Survival advantage of treosulfan plus fludarabine before allogeneic hematopoietic cell transplantation for older or comorbid patients with myeloid malignancies. Transplant Cell Ther. 2021;27:916.e911\u20136. https:\/\/doi.org\/10.1016\/j.jtct.2021.07.020.","journal-title":"Transplant Cell Ther"},{"key":"1701_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/ajh.21240","volume":"83","author":"D Baronciani","year":"2008","unstructured":"Baronciani D, Rambaldi A, Iori AP, Di Bartolomeo P, Pilo F, Pettinau M, et al. Treosulfan\/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol. 2008;83:717\u201320. https:\/\/doi.org\/10.1002\/ajh.21240. e-pub ahead of print 2008\/07\/16.","journal-title":"Am J Hematol"},{"key":"1701_CR39","first-page":"4209","volume":"6","author":"ME Scheulen","year":"2000","unstructured":"Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res. 2000;6:4209\u201316. e-pub ahead of print 2000\/12\/06.","journal-title":"Clin Cancer Res"},{"key":"1701_CR40","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C. et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55:1114\u201325. https:\/\/doi.org\/10.1038\/s41409-020-0803-y.","journal-title":"Bone Marrow Transplant"},{"key":"1701_CR41","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21:1046\u201353. https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.005. e-pub ahead of print 2015\/02\/18.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1701_CR42","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bbmt.2014.01.025","volume":"20","author":"D Chihara","year":"2014","unstructured":"Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed\/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transpl. 2014;20:684\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2014.01.025. e-pub ahead of print 2014\/02\/05.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1701_CR43","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3389\/fonc.2019.00892","volume":"9","author":"A Colita","year":"2019","unstructured":"Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, et al. LEAM vs. BEAM vs. CLV conditioning regimen for autologous stem cell transplantation in malignant lymphomas. retrospective comparison of toxicity and efficacy on 222 patients in the first 100 days after transplant, on behalf of the romanian society for bone marrow transplantation. Front Oncol. 2019;9:892 https:\/\/doi.org\/10.3389\/fonc.2019.00892. e-pub ahead of print 2019\/09\/26.","journal-title":"Front Oncol"},{"key":"1701_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/bmt.2008.299","volume":"43","author":"S McCann","year":"2009","unstructured":"McCann S, Schwenkglenks M, Bacon P, Einsele H, D\u2019Addio A, Maertens J, et al. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transpl. 2009;43:141\u20137. https:\/\/doi.org\/10.1038\/bmt.2008.299. e-pub ahead of print 2008\/09\/09.","journal-title":"Bone Marrow Transpl"},{"key":"1701_CR45","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jaad.2007.12.037","volume":"58","author":"IS Rosman","year":"2008","unstructured":"Rosman IS, Lloyd BM, Hayashi RJ, Bayliss SJ. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol. 2008;58:575\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2007.12.037. e-pub ahead of print 2008\/02\/06.","journal-title":"J Am Acad Dermatol"},{"key":"1701_CR46","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","volume":"121","author":"ML Sorror","year":"2013","unstructured":"Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121:2854\u201363. https:\/\/doi.org\/10.1182\/blood-2012-09-455063. e-pub ahead of print 2013\/01\/29.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01701-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T17:14:57Z","timestamp":1657214097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01701-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1701"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01701-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IH received honoraria from Novartis and ABBVIE and has obtained travel, accommodation or expenses from medac GmbH, Janssen-Ciliag, Jazz Pharmaceuticals and Celgene. AH received research support by Novartis, BMS, Pfizer, and Incyte. The other authors do not declare any conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Based on Thuringian law and our clinical Ethics Committee, reports providing routinely collected data do not need approval by Ethics Committee. Written informed consent was obtained from our patients for publication in this report. A copy of written consent is available for review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}